Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333087 | 0.85 | F2 (0.33) | ALDH1A1F2 | |
| SCHEMBL3338219 | 0.81 | SYK (0.35) | — | |
| SCHEMBL3336545 | 0.81 | SYK (0.35) | — | |
| SCHEMBL13302748 | 0.79 | SYK (0.36) | — | |
| SCHEMBL3335928 | 0.79 | SYK (0.36) | — | |
| SCHEMBL3335870 | 0.79 | F11 (0.35) | — | |
| SCHEMBL3333105 | 0.77 | F11 (0.44) | — | |
| SCHEMBL3333202 | 0.75 | SYK (0.32) | — | |
| SCHEMBL13899711 | 0.75 | L3MBTL1 (0.37) | F2 | |
| SCHEMBL13302752 | 0.75 | L3MBTL1 (0.37) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1871741-A2 | SUBSTITUTED AZETIDINONES | Daiamed, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | ALDH1A1 2503/4885RAB9A 453/4885F2 37/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | ALDH1A1 2503/4885RAB9A 453/4885F2 37/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | ALDH1A1 2503/4885RAB9A 453/4885F2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.